The cervical screening program was established to identify increased risk of cervical cancer in women aged between 30 and 60 years. Cervical cancer is caused by a long-term virus infection: the human papillomavirus (HPV). Early detection of HPV can prevent cervical cancer. The Biobank BVO contains left-over cytological material from the cervical screening program. The ambition of the BVO Biobank is to make this residual material available for scientific research to optimize the current cervical cancer screening program. Moreover, it aims to create a more personalized intervention by promoting better understanding of the oncogenic progression and transformation of high-risk HPV (hrHPV) infected cells and the identification/testing of biomarkers or biomarker profiles.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Costs for internal researchers in case of request for samples26 May 2020
As of January 1, 2020, internal researchers who request samples from the Radboud Biobank will only be charged for the number of samples received.read more